Health: Pancreatic Cancer

Lord Aberdare Excerpts

Monday 21st November 2022 Lords Chamber

[Lord Markham (Con)]

I understand that the leader in this field is GRAIL. This blood screening is happening in America right now, and NICE is undertaking studies in this field to see whether it should be brought to the UK. We will have its findings. I agree that pancreatic cancer is an area where early detection is key. It is not just about the screening but about people going to their doctor if they have any concerns at all, as I say. We have non-specific symptoms pathways to help doctors to detect what is wrong.

[Lord Aberdare (CB)]

My Lords, the UK ranks 29th of 33 countries for five-year pancreatic cancer survival rates. At the very least, we should ensure that pancreatic cancer patients get the best possible treatments in the short time usually available to them, with over half dying within three months. One such treatment is pancreatic enzyme replacement therapy—PERT—which helps them to eat and digest their food, but only about half of pancreatic cancer sufferers are offered this treatment. What are the Government doing to understand why this is the case and to ensure that all pancreatic cancer patients who need PERT are offered it?

[Lord Markham (Con)]

I thank the noble Lord. This case has also been brought forward by the noble Lord, Lord Moynihan, who could not be here today, but he is very keen on this as well. We have now put PERT into NICE guidelines, so it should be offered. I am meeting my noble friend Lord Moynihan to make sure that these things are being taken up, and I would be happy to extend that invitation to the noble Lord.